Neogen (NEOG)
(Delayed Data from NSDQ)
$16.78 USD
+0.73 (4.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.78 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.78 USD
+0.73 (4.55%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $16.78 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth F Momentum D VGM
Zacks News
Neogen (NEOG) Q2 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Growth across the Food Safety and Animal Safety segments drives Neogen's (NEOG) Q2 revenues.
Neogen (NEOG) Rises 7.9% Since Q1 Earnings: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) recent product launches and strong global presence.
Neogen (NEOG) Benefits From Advanced Portfolio, Global Growth
by Zacks Equity Research
Barring Australia and China, solid international operations also buoy optimism for Neogen (NEOG).
HEXO (HEXO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
HEXO (HEXO) delivered earnings and revenue surprises of -250% and 19.23%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Neogen (NEOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Healthy Top-Line Growth Buoy Jabil (JBL) Q1 Earnings?
by Zacks Equity Research
Backed by solid demand in key end markets, diligent execution of operational plans and skillful management of supply chain dynamics, Jabil (JBL) is likely to record healthy fiscal first-quarter revenues.
Neogen's (NEOG) Synergize Disinfectant Now Widely Available
by Zacks Equity Research
Availability of Neogen's (NEOG) Synergize Disinfectant in other markets is expected to enhance global biosecurity portfolios, thereby safeguarding the food chain from harmful diseases.
Neogen (NEOG) Down 13.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Neogen (NEOG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Neogen (NEOG) Q1 Earnings Top Estimates, Operating Margin Dips
by Zacks Equity Research
Neogen's (NEOG) allergen and environmental sanitation product lines decline due to reduced buying patterns from customers and supply chain disruptions of certain products.
Neogen (NEOG) Q1 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of -6.25% and 2.51%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stock?
Neogen (NEOG) Launches Test for Detection of Cashew Allergen
by Zacks Equity Research
Neogen's (NEOG) new quantitative test shows a high level of specificity to very low levels of cashew protein (down to 0.2 ppm).
Neogen (NEOG) Finalizes Food Safety Business Merger With 3M
by Zacks Equity Research
The combination of Neogen (NEOG) and 3M's Food Safety division will capitalize on the ongoing growth trends in sustainability, food safety and supply chain integrity.
Phibro Animal Health (PAHC) Q4 Earnings Lag Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of -10% and 0.98%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
LabCorp (LH) Q2 Earnings Top Estimates, Raises '22 EPS View
by Zacks Equity Research
LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.
Hologic (HOLX) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Hologic (HOLX) reports better-than-expected results in the fiscal third quarter with robust sales performance in the GYN Surgical business.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.
Thermo Fisher (TMO) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Specialty Diagnostics segment revenues is disappointing.
West Pharmaceutical (WST) Q2 Earnings Beat, FY22 View Cut
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter earnings reflect strength in the Proprietary Products segment.
Merit Medical (MMSI) Q2 Earnings Beat, FY22 View Revised
by Zacks Equity Research
Merit Medical (MMSI), in the second quarter, benefits from revenue growth in both its segments and from all product categories within its Cardiovascular unit.
Neogen (NEOG) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Neogen (NEOG) delivers better-than-expected results for the fiscal fourth quarter, with robust segmental performance driving the top line.
Neogen (NEOG) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Neogen (NEOG) delivered earnings and revenue surprises of 12.50% and 1.25%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Neogen's (NEOG) robust segmental performance and notable product launches instill investors' confidence.
Neogen (NEOG) to Offer New Biosecurity Solution in Canada
by Zacks Equity Research
Neogen's (NEOG) newest addition to the biosecurity portfolio is anticipated to curb the spread of diseases like COVID-19 and avian influenza.